FiercePharma
`
`Select another site Advertise Contact
`
`SEARCH
`
`Free Daily Pharma Industry Newsletter Every business day, FiercePharma updates pharmaceutical executives on the latest Pharma industry news
`and deals. Stay up to date on:
`Pharma Company News ∣ Generic Drug Companies ∣ Pharmaceutical Marketing & Sales ∣ FDA Regulations & Warnings ∣ Phase IV Clinical Trials
`Click here to see a sample.
`
`We never sell or give away your contact information. Our readers' trust comes first.
`
`EMAIL ADDRESS
`
`NEWS TOPICS ANALYSIS FEATURES LIBRARY EVENTS JOBS MARKETPLACE
`
`Topics: Sales and Marketing
`The top 10 bestselling multiple sclerosis drugs
`of 2013
`September 9, 2014
`
`SHARE
`
`Want a surefire way to shake up a drug market? Introduce new
`medication options that make it easier for patients to manage
`their disease. MS drugmakers would know; their market is all of a
`sudden full of them.
`
`71
`
`Tweet
`
`115
`
`Share
`
`18
`
`Like
`
`0
`
`TOOLS
`
`Comment
`
`Print
`
`Reprint
`
`For one, a gamechanging trio of pills is providing an alternative
`to injections. Novartis' ($NVS) Gilenya hit first in September
`2010, followed by Sanofi's ($SNY) Aubagio and Biogen Idec's
`($BIIB) Tecfidera. Two of those three, Gilenya and Tecfidera, nabbed spots on
`our list of Top 15 drug launch superstars after hitting the ground running. They're
`primed to keep moving up the food chain, too.
`
`Then, there are new, longacting meds like the 40mg version of bestseller
`Copaxone, which hit the market just in time for maker Teva ($TEVA) to start
`converting patients ahead of a bumpedup May patent expiration. With a
`Supreme Court appeal in its patent case set to begin soon, Teva's seeing
`patients switch over to the new formulainjected thrice weekly, as opposed to
`dailyat a rate that has so far both surprised and impressed analysts. Biogen
`Idec, too, recently snagged the FDA's favor for its own longlasting med, a
`followup to Avonexdubbed Plegridythat requires injection only once every
`two weeks.
`
`Drugmakers are looking for more subtle yet significant ways to make their MS
`meds more attractive to patients, too. Take Biogen's Avonex Pen, for instance,
`greenlighted by the FDA the year before last. The Massachusetts biotech billed
`it as the first "intramuscular autoinjector" approved for MS and one it hoped
`would reduce "injection anxiety" and "pain."
`
`All of these factors are helping
`redraw the MS treatment map, and
`we could soon be looking at a new
`king on the MS throne. So quick
`check out our review of how the top
`10 products stacked up in 2013,
`based on data from
`
`Like what you're reading?
`
`Click here to get more news like
`this delivered to your inbox every
`weekday >
`
`FOLLOW US
`
`J O I N 1 5 0 , 0 0 0 + I N S I D E R S
`SIGN UP FOR OUR
`NEWSLETTER
`
`EMAIL ADDRESS
`
`FiercePharma is the pharma industry's daily monitor,
`with a special focus on pharmaceutical company news
`and the market development of FDA approved
`products. Join thousands of pharma industry leaders
`who get FiercePharma via daily email. Sign up today!
`
`POPULAR STORIES
`
`MOST READ MOST SHARED
`
`Investors: GSK chief Witty is safe for now, but one
`more strike and he's out
`The legal death of Actavis' Namenda strategy spells
`doom for the 'hard switch'
`Pfizer could buy GSK, but would Shire or Perrigo
`offer better targets?
`GSK, Pfizer among Big Pharmas bailing on Chinese
`sales as provinces squeeze prices
`Should Pfizer snap up GSK? Well, a megadeal
`could speed up a split
`
`THE LIBRARY: WEBINAR
`Using ePRO with Smart Devices: A Case Study
`
`| WEDNESDAY, JUNE 10TH | 1PM ET / 10AM PT |
`
`5/27/2015
`
`The top 10 best-selling multiple sclerosis drugs of 2013 - FiercePharma
`
`http://www.fiercepharma.com/special-reports/top-10-best-selling-multiple-sclerosis-drugs-2013
`
`1/4
`
`MYLAN PHARMS. INC. EXHIBIT 1115 PAGE 1
`
`
`
`Select another site Advertise Contact
`
`SEARCH
`
`Free Daily Pharma Industry Newsletter Every business day, FiercePharma updates pharmaceutical executives on the latest Pharma industry news
`and deals. Stay up to date on:
`Pharma Company News ∣ Generic Drug Companies ∣ Pharmaceutical Marketing & Sales ∣ FDA Regulations & Warnings ∣ Phase IV Clinical Trials
`Click here to see a sample.
`
`We never sell or give away your contact information. Our readers' trust comes first.
`
`EMAIL ADDRESS
`
`NEWS TOPICS ANALYSIS FEATURES LIBRARY EVENTS JOBS MARKETPLACE
`
`Topics: Sales and Marketing
`The top 10 bestselling multiple sclerosis drugs
`of 2013
`September 9, 2014
`
`SHARE
`
`Want a surefire way to shake up a drug market? Introduce new
`medication options that make it easier for patients to manage
`their disease. MS drugmakers would know; their market is all of a
`sudden full of them.
`
`71
`
`Tweet
`
`115
`
`Share
`
`18
`
`Like
`
`0
`
`TOOLS
`
`Comment
`
`
`Reprint
`
`For one, a gamechanging trio of pills is providing an alternative
`to injections. Novartis' ($NVS) Gilenya hit first in September
`2010, followed by Sanofi's ($SNY) Aubagio and Biogen Idec's
`($BIIB) Tecfidera. Two of those three, Gilenya and Tecfidera, nabbed spots on
`our list of Top 15 drug launch superstars after hitting the ground running. They're
`primed to keep moving up the food chain, too.
`
`Then, there are new, longacting meds like the 40mg version of bestseller
`Copaxone, which hit the market just in time for maker Teva ($TEVA) to start
`converting patients ahead of a bumpedup May patent expiration. With a
`Supreme Court appeal in its patent case set to begin soon, Teva's seeing
`patients switch over to the new formulainjected thrice weekly, as opposed to
`dailyat a rate that has so far both surprised and impressed analysts. Biogen
`Idec, too, recently snagged the FDA's favor for its own longlasting med, a
`followup to Avonexdubbed Plegridythat requires injection only once every
`two weeks.
`
`Drugmakers are looking for more subtle yet significant ways to make their MS
`meds more attractive to patients, too. Take Biogen's Avonex Pen, for instance,
`greenlighted by the FDA the year before last. The Massachusetts biotech billed
`it as the first "intramuscular autoinjector" approved for MS and one it hoped
`would reduce "injection anxiety" and "pain."
`
`All of these factors are helping
`redraw the MS treatment map, and
`we could soon be looking at a new
`king on the MS throne. So quick
`check out our review of how the top
`10 products stacked up in 2013,
`based on data from
`
`Like what you're reading?
`
`Click here to get more news like
`this delivered to your inbox every
`weekday >
`
`FOLLOW US
`
`J O I N 1 5 0 , 0 0 0 + I N S I D E R S
`SIGN UP FOR OUR
`NEWSLETTER
`
`EMAIL ADDRESS
`
`FiercePharma is the pharma industry's daily monitor,
`with a special focus on pharmaceutical company news
`and the market development of FDA approved
`products. Join thousands of pharma industry leaders
`who get FiercePharma via daily email. Sign up today!
`
`POPULAR STORIES
`
`MOST READ MOST SHARED
`
`Investors: GSK chief Witty is safe for now, but one
`more strike and he's out
`The legal death of Actavis' Namenda strategy spells
`doom for the 'hard switch'
`Pfizer could buy GSK, but would Shire or Perrigo
`offer better targets?
`GSK, Pfizer among Big Pharmas bailing on Chinese
`sales as provinces squeeze prices
`Should Pfizer snap up GSK? Well, a megadeal
`could speed up a split
`
`THE LIBRARY: WEBINAR
`Using ePRO with Smart Devices: A Case Study
`
`| WEDNESDAY, JUNE 10TH | 1PM ET / 10AM PT |
`
`5/27/2015
`
`The top 10 best-selling multiple sclerosis drugs of 2013 - FiercePharma
`
`http://www.fiercepharma.com/special-reports/top-10-best-selling-multiple-sclerosis-drugs-2013
`
`1/4
`
`MYLAN PHARMS. INC. EXHIBIT 1115 PAGE 1
`
`
`
`EvaluatePharma. The bestsellers
`list will look different before you know it. Carly Helfand (email | Twitter) and
`Eric Palmer (email | Twitter)
`
`1
`
`2
`
`3
`
`4
`
`5
`
`Copaxone
`
`Avonex
`
`Rebif
`
`Gilenya
`
`Tysabri
`
`6
`
`7
`
`8
`
`9
`
`Betaseron/Betaferon
`
`Tecfidera
`
`Ampyra
`
`H.P. Acthar Gel
`
`10 Aubagio
`
`NEXT
`
`PRESENTED BY: RHO
`
`Interest in using electronic patient
`reported outcomes (ePRO) on smart
`devices is on the rise. In this webinar, Emily
`Cantrell and Becky Baggett will share lessons
`learned working on a large phase 3 pain study
`that utilizes ePRO on tablet devices. Register
`Now!
`
`MORE ITEMS
`
`Filed Under multiple sclerosis
`
`COMMENTS
`9 Comments
`
`FiercePharma
`
` Recommend
`
`
`
` Share⤤
`
`Join the discussion…
`
` Login
`
`1
`Sort by Best
`
`Leslye Gower • 9 months ago
`Huh. What poison will they think of next?
`
`• Reply •
`Share ›
` 1
`
`
`Lynne Heal
` • a month ago
`> Leslye Gower
`One MS drug even had furniture polish added to it
`
`• Reply •
`Share ›
`
`
`Lynne Heal • 6 months ago
`Many MS drugs are deadly they all need to be scrutinised along with everyone whos
`promoted them. This is also why a cure for MS will never be found because too
`many have made trillions from MS drugs all having profits , shares and
`commmissions alongside very high salarys its so easy to work out whats going on
`in MS http://www.newsmax.com/Health/... http://www.independent.co.uk/l...
`
`• Reply •
`Share ›
`
`
`The Dame Judy Dench
` • 4 months ago
`> Lynne Heal
`what treatment do you suggest we take?
`
`• Reply •
`Share ›
`
`
`Lynne Heal
` • 4 months ago
`> The Dame Judy Dench
`CCSVI is whats needed it works and is NOT deadly at all here is
`atlast someone being sued for naysaying CCSVI and knows many
`more will be too http://news.nationalpost.com/n...
`
`• Reply •
`Share ›
`
`
`Bill Anderson
` • a month ago
`> Lynne Heal
`CCSVI has been deadly, not to mention that it doesnt work
`
`• Reply •
`Share ›
`
`
`LATEST COMMENTARY
`
`Teva's recent history gives Mylan chairman plenty of
`antibuyout zingers
`Indivior CEO looks beyond 2015 after troubled
`Reckitt pharma unit's spinoff
`Get out your binoculars for FiercePharma's
`traditional holiday trendspotting
`Pfizer believes a dose of confidence will help it sell
`biosimilars
`We publish, you pick: FiercePharma's 10 bestread
`stories of 2014
`
`EVENTS
`
`Pharmaceutical Manufacturing/Processing
`Equipment & Packaging for Sale
`
`Sensors Expo & Conference
`June 911 — Long Beach, CA
`
`BIO International Convention
`June 1518, 2015 — Pennsylvania Convention
`Center
`MORE EVENTS
`
`
`
`Lynne Heal
` • a month ago
`> Bill Anderson
`MS drugs are MORE deadly http://www.family-
`announcement...
`• Reply •
`
`
`Share ›
`
`
`
`5/27/2015
`
`The top 10 best-selling multiple sclerosis drugs of 2013 - FiercePharma
`
`http://www.fiercepharma.com/special-reports/top-10-best-selling-multiple-sclerosis-drugs-2013
`
`2/4
`
`△
`
`▽
`
`△
`
`▽
`
`△
`
`▽
`
`△
`
`▽
`
`△
`
`▽
`
`△
`
`▽
`
`△
`
`▽
`
`MYLAN PHARMS. INC. EXHIBIT 1115 PAGE 2
`
`
`
`
`
`Reply
`
`Share ›
`
`
`
`painkills2 • 9 months ago
`In 2014, will the list include Sativex?
`
`• Reply •
`Share ›
`
`
`Lynne Heal
` • 4 months ago
`> painkills2
`Sativex is not like MS drugs this drug helps the pain yet denied. Its so easy
`to work out whats really going on in MS
`
`• Reply •
`Share ›
` 1
`
`
`ALSO ON FIERCEPHARMA
`German cost watchdogs look askance
`at uniQure's $1.4M gene …
`2 comments • 6 days ago
`AvatarDrMedValue — May I ask you to redo
`your homework and consult a German
`reimbursement specialist before you …
`Study says no good has come from
`FDA's action on gout drug colchicine
`1 comment • 2 months ago
`AvatarMichael A. Swit — Please note that FDA
`has had the power to regulate the safety
`of drugs since 1938 when the …
`
`WHAT'S THIS?
`With U.S. sales suffering, GSK plots
`changes to quota-free pay model
`1 comment • a month ago
`Avatarlbhajdu1 . — GSK is paying under the
`table kickbacks to Richard Pan. I think
`that needs investigation. They stand …
`GSK shingles shot might trump
`Merck's Zostavax, analysts say
`2 comments • 2 months ago
`AvatarTammi Apodoca — I'm 35 years old
`female and I tested positive for herpes
`type 2 in 2010. I did get bad …
`
`Subscribe
`
`✉
`
`d
`
`Add Disqus to your site
`
`Privacy
`
`
`
`PRESS RELEASES
`Quintiles Launches New Solution to Meet Needs of AsiaPacific
`Emerging Biopharmaceutical Companies
`Myomo, Inc. Partners with Paralyzed Veterans of America
`Study Shows Sorin Group's Phospholipid Reduction Treatment
`Significantly Reduces Calcium Absorption in Tissue Heart Valves to Help
`Enhance Valve Durability
`Bayer has outstanding perspectives as a pure Life Science company
`UMD Researcher Developing Virtual "CyberHeart" for Testing &
`Improving Implantable Cardiac Devices
`More Press Releases
`
`FEATURED JOBS
`> Need a job? Need to hire? Visit our jobs site.
`
`A publication of
`
`FiercePharma is the pharma
`industry's daily monitor, with
`a special focus on
`pharmaceutical company
`news and the market
`development of FDA
`approved products. Join
`150,000+ pharma industry
`leaders who get
`FiercePharma via daily
`email. Click here to get your
`free weekly email briefing
`today!
`
`The FierceMarkets Network:
`Telecom
`FierceCable
`FierceDeveloper
`FierceWireless:Europe
`FierceWirelessTech
`FierceOnlineVideo
`FierceTelecom
`FierceWireless
`
`Marketing & Retail
`FierceCMO
`FierceMobileMarketer
`FierceRetail
`FierceRetailIT
`FierceMobileRetail
`
`Healthcare
`FierceEMR
`FierceHealthcare
`FierceHealthFinance
`FierceHealthIT
`FierceHealthPayer
`FierceHealthPayerAntiFraud
`FierceMobileHealthcare
`FiercePracticeManagement
`Hospital Impact
`
`Government
`FierceGovernment
`FierceGovernmentIT
`FierceHomelandSecurity
`FierceMobileGovernment
`FierceCities
`FierceGovHealthIT
`
`Life Sciences
`FierceBiotechResearch
`FierceBiotech
`FierceBiotechIT
`FierceCRO
`FierceDiagnostics
`FierceDrugDelivery
`FierceMedicalDevices
`FiercePharma
`FiercePharmaAsia
`FiercePharmaManufacturing
`FiercePharmaMarketing
`FierceVaccines
`FierceAnimalHealth
`
`Enterprise IT
`FierceBigData
`FierceCIO
`FierceContentManagement
`FierceDevOps
`FierceEnterpriseCommunications
`FierceITSecurity
`FierceMobileIT
`
`Energy
`FierceEnergy
`SmartGridNews
`
`Finance
`FierceCFO
`FierceFinanceIT
`
`Home Subscribe Manage Newsletter Subscriptions Advertise Contact Mobile Apps RSS Privacy Editors List in Marketplace
`© 2015 FierceMarkets, a division of Questex Media Group LLC. All rights reserved.
`
`5/27/2015
`
`The top 10 best-selling multiple sclerosis drugs of 2013 - FiercePharma
`
`http://www.fiercepharma.com/special-reports/top-10-best-selling-multiple-sclerosis-drugs-2013
`
`3/4
`
`△
`
`▽
`
`△
`
`▽
`
`△
`
`▽
`
`MYLAN PHARMS. INC. EXHIBIT 1115 PAGE 3
`
`
`
`5/27/2015
`
`The top 10 best-selling multiple sclerosis drugs of 2013 - FiercePharma
`
`http://www.fiercepharma.com/special-reports/top-10-best-selling-multiple-sclerosis-drugs-2013
`
`4/4
`
`MYLAN PHARMS. INC. EXHIBIT 1115 PAGE 4
Accessing this document will incur an additional charge of $.
After purchase, you can access this document again without charge.
Accept $ Charge
Still Working On It
This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.
Give it another minute or two to complete, and then try the refresh button.
A few More Minutes ... Still Working
It can take up to 5 minutes for us to download a document if the court servers are running slowly.
Thank you for your continued patience.
This document could not be displayed.
We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.
Your account does not support viewing this document.
You need a Paid Account to view this document. Click here to change your account type.
Your account does not support viewing this document.
Set your membership
status to view this document.
With a Docket Alarm membership, you'll
get a whole lot more, including:
- Up-to-date information for this case.
- Email alerts whenever there is an update.
- Full text search for other cases.
- Get email alerts whenever a new case matches your search.
One Moment Please
The filing “” is large (MB) and is being downloaded.
Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.
Your document is on its way!
If you do not receive the document in five minutes, contact support at support@docketalarm.com.
Sealed Document
We are unable to display this document, it may be under a court ordered seal.
If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.
Access Government Site
